NL-OMON50328已完成2 期
Re-induction of a systemic immune response after initial response with immune therapy with radiotherapy in metastatic or locally recurrent lung cancer - Remission-Induction
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Non small cell lung cancer
- •- CR, PR or SD initially under immune therapy (possibly combined with
- •chemotherapy)
- •- Progressive disease
- •- Able to continue the same immune therapy (i.e. no adverse events grade 3 or
排除标准
- •- Patients with any grade 3 or higher toxicity from previous therapy;
- •- Patients who are not eligible for continuation of the immune therapy
- •according to standard practice;
- •- Corticosteroids in a dose of at maximum 10mg prednisone or equivalent per
研究者
相似试验
招募中
不适用
CIMAvax-EGF in different maintenance schemeson small cell lung cancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesNSCLCRPCEC00000368Center of Molecular Immunology (CIM)42
进行中（未招募）
不适用
Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1?infected patients (<100 CD4+ T cells/?L) taking antiretroviral regimens based on dolutegravir or ritonavir-boosted darunavir (the AdvanZ-4 Trial).tratement HIV infectionEUCTR2014-002281-70-ESFundació Clínic per a la Recerca Biomèdica
进行中（未招募）
不适用
Determination of immune response after sequential pneumococcal vaccination using the 7-valent conjugate pneumococcal and the 23-valent pneumococcal polysaccharide vaccine in renal transplant recipientsEUCTR2007-004590-25-ATMedical University of Vienna
招募中
2 期
Immune induction strategies to improve response to immune checkpoint blockade in triple negative breast cancer (TNBC) patients: the TONIC-2 trialBreast cancerNL-OMON54994ederlands Kanker Instituut34
进行中（未招募）
1 期
RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVALUMAB/NAB-PACLITAXEL: THE ATRiBRAVE TRIAADVANCED TRIPLE NEGATIVE BREAST CANCERMedDRA version: 26.0Level: LLTClassification code: 10006216Term: Breast carcinoma stage IV Class: 10029104MedDRA version: 26.0Level: LLTClassification code: 10006215Term: Breast carcinoma stage III Class: 10029104MedDRA version: 20.1Level: LLTClassification code: 10006212Term: Breast carcinoma recurrent Class: 10029104CTIS2024-513721-23-00IFOM Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets37